Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

HIIT workouts may stop diabetes from coming back

NCT ID NCT07565935

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether a home-based high-intensity interval training (HIIT) program can help people who have reversed their type 2 diabetes keep it from returning. Twenty adults who completed the NHS Path to Remission programme will either do HIIT three times a week or continue their usual routine for 16 weeks. The goal is to see if HIIT protects the pancreas cells that produce insulin, which is key for long-term remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults between the age of 18-70 years * Ability to provide informed consent * Completed the NHS Path to Remission programme and achieved diabetes remission (HbA1c \<48mmol/mol (6.5%), and off diabetes medications for at least three months) Exclusion Criteria: * BMI \> 40kg/m2 * Current participation in a formal exercise regime * Current pregnancy or breastfeeding * Uncontrolled hypertension (blood pressure \>160/100mmHg) * History of cardiovascular disease: * Symptomatic angina * Heart failure (class III/IV) * Significant arrhythmias * Right to left cardiac shunt * Recent acute coronary syndrome * Severe aortic valvular disease * Active cardiac infection * Background of the following respiratory diseases: * Pulmonary hypertension * Significant COPD * Uncontrolled asthma * History of malignancy undergoing current treatment or palliation * Presence of significant musculoskeletal, neurological or cerebrovascular disease * Any other medical condition deemed by the investigators to preclude inclusion into the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity / overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Nottingham, Royal Derby Hospital Centre

    Derby, DE22 3DT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.